HK1243713A1 - 一种化合物的固体形式及其使用方法 - Google Patents

一种化合物的固体形式及其使用方法 Download PDF

Info

Publication number
HK1243713A1
HK1243713A1 HK18103068.1A HK18103068A HK1243713A1 HK 1243713 A1 HK1243713 A1 HK 1243713A1 HK 18103068 A HK18103068 A HK 18103068A HK 1243713 A1 HK1243713 A1 HK 1243713A1
Authority
HK
Hong Kong
Prior art keywords
added
chloro
mixture
ethoxybenzyl
phenyl
Prior art date
Application number
HK18103068.1A
Other languages
English (en)
Chinese (zh)
Inventor
Margaret De Paul Susan
Perlberg Anett
Mangzhu Zhao Matthew
Original Assignee
Lexicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals, Inc. filed Critical Lexicon Pharmaceuticals, Inc.
Publication of HK1243713A1 publication Critical patent/HK1243713A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/14Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
HK18103068.1A 2008-07-17 2018-03-02 一种化合物的固体形式及其使用方法 HK1243713A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17
US61/081,423 2008-07-17

Publications (1)

Publication Number Publication Date
HK1243713A1 true HK1243713A1 (zh) 2018-07-20

Family

ID=41137707

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103068.1A HK1243713A1 (zh) 2008-07-17 2018-03-02 一种化合物的固体形式及其使用方法

Country Status (29)

Country Link
US (2) US8217156B2 (cg-RX-API-DMAC7.html)
EP (1) EP2332947B1 (cg-RX-API-DMAC7.html)
JP (2) JP2011528366A (cg-RX-API-DMAC7.html)
KR (2) KR20170010069A (cg-RX-API-DMAC7.html)
CN (2) CN107629097A (cg-RX-API-DMAC7.html)
AR (1) AR072807A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009270973B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916191A2 (cg-RX-API-DMAC7.html)
CA (1) CA2730931A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001595A1 (cg-RX-API-DMAC7.html)
CO (1) CO6351797A2 (cg-RX-API-DMAC7.html)
DK (1) DK2332947T3 (cg-RX-API-DMAC7.html)
ES (1) ES2656357T3 (cg-RX-API-DMAC7.html)
HK (1) HK1243713A1 (cg-RX-API-DMAC7.html)
HU (1) HUE035400T2 (cg-RX-API-DMAC7.html)
IL (1) IL210269A (cg-RX-API-DMAC7.html)
MX (1) MX2011000503A (cg-RX-API-DMAC7.html)
NO (1) NO2332947T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ590184A (cg-RX-API-DMAC7.html)
PE (1) PE20100260A1 (cg-RX-API-DMAC7.html)
PL (1) PL2332947T3 (cg-RX-API-DMAC7.html)
PT (1) PT2332947T (cg-RX-API-DMAC7.html)
RU (1) RU2505543C2 (cg-RX-API-DMAC7.html)
SG (1) SG185317A1 (cg-RX-API-DMAC7.html)
TW (1) TWI472521B (cg-RX-API-DMAC7.html)
UA (1) UA106048C2 (cg-RX-API-DMAC7.html)
UY (1) UY31992A (cg-RX-API-DMAC7.html)
WO (1) WO2010009197A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100175B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
ATE530558T1 (de) 2007-07-26 2011-11-15 Lexicon Pharmaceuticals Inc Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2728246T3 (es) * 2012-11-20 2019-10-23 Lexicon Pharmaceuticals Inc Inhibidores del cotransportador 1 de sodio-glucosa
US20210317140A1 (en) 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
RU2751634C2 (ru) 2015-07-30 2021-07-15 Майкробиал Кемистри Рисерч Фаундейшн Новый эффективный аминогликозидный антибиотик против бактерий с множественной лекарственной резистентностью
CN109195980B (zh) * 2016-05-25 2022-05-17 苏州科睿思制药有限公司 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
AU2017344882A1 (en) 2016-10-19 2019-03-28 Boehringer Ingelheim International Gmbh Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
WO2020068661A1 (en) * 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
WO2020089026A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
US20220324897A1 (en) * 2019-07-05 2022-10-13 Shandong Danhong Pharmaceutical Co., Ltd. Crystal form of sglt inhibitor and application thereof
EP3771718A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
WO2022144465A1 (en) 2021-01-04 2022-07-07 Charité-Universitätsmedizin Berlin Sotagliflozin for improving left atrial function
US20220370485A1 (en) 2021-01-14 2022-11-24 Lexicon Pharmaceuticals, Inc. Compounds and methods for treating or preventing cardiovascular diseases and conditions
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
WO2025072413A1 (en) 2023-09-28 2025-04-03 Lexicon Pharmaceuticals, Inc. Methods of treating type 1 diabetes and kidney disease
US20250114323A1 (en) 2023-10-06 2025-04-10 Lexicon Pharmaceuticals, Inc. Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy
PL446852A1 (pl) * 2023-11-27 2025-06-02 Politechnika Rzeszowska im. Ignacego Łukasiewicza Układ doprowadzający wodę do pralki

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006089872A1 (en) 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
ATE530558T1 (de) * 2007-07-26 2011-11-15 Lexicon Pharmaceuticals Inc Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
US9067962B2 (en) 2015-06-30
AU2009270973B2 (en) 2014-01-30
US8217156B2 (en) 2012-07-10
RU2011105797A (ru) 2012-08-27
US20100016422A1 (en) 2010-01-21
WO2010009197A1 (en) 2010-01-21
EP2332947A1 (en) 2011-06-15
KR20170010069A (ko) 2017-01-25
AR072807A1 (es) 2010-09-22
JP2016041701A (ja) 2016-03-31
TW201006808A (en) 2010-02-16
CN107629097A (zh) 2018-01-26
EP2332947B1 (en) 2017-11-01
UA106048C2 (uk) 2014-07-25
UY31992A (es) 2010-02-26
PE20100260A1 (es) 2010-04-16
ZA201100175B (en) 2012-03-28
IL210269A0 (en) 2011-03-31
CN102112483A (zh) 2011-06-29
TWI472521B (zh) 2015-02-11
HUE035400T2 (en) 2018-05-02
IL210269A (en) 2015-06-30
ES2656357T3 (es) 2018-02-26
CO6351797A2 (es) 2011-12-20
NZ590184A (en) 2012-09-28
CL2009001595A1 (es) 2010-07-19
KR20110031196A (ko) 2011-03-24
AU2009270973A1 (en) 2010-01-21
BRPI0916191A2 (pt) 2017-08-29
JP6283337B2 (ja) 2018-02-21
JP2011528366A (ja) 2011-11-17
KR101707246B1 (ko) 2017-02-15
MX2011000503A (es) 2011-03-01
DK2332947T3 (da) 2018-01-29
NO2332947T3 (cg-RX-API-DMAC7.html) 2018-03-31
US20130165395A1 (en) 2013-06-27
RU2505543C2 (ru) 2014-01-27
PT2332947T (pt) 2018-02-06
PL2332947T3 (pl) 2018-04-30
SG185317A1 (en) 2012-11-29
CA2730931A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
HK1243713A1 (zh) 一种化合物的固体形式及其使用方法
CN101801989B (zh) 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物
EP2324002B1 (en) Processes for the preparation of sglt2 inhibitors
KR101837488B1 (ko) 광학적으로 순수한 벤질-4-클로로페닐-c-글루코사이드 유도체
WO2012025857A1 (en) Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
US10703772B2 (en) Processes for the preparation of SGLT-2 inhibitors, intermediates thereof
HK1153480A (en) Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use
CN121135699A (zh) 一类含有四氢呋喃结构的鎓盐类衍生物和制备方法及其应用
US20250129055A1 (en) Glucoside derivative, and preparation method therefor and application thereof
HK1153742B (en) Processes for the preparation of sglt2 inhibitors
HK1143982B (en) Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
WO2012162115A2 (en) Process for the preparation of compounds useful as inhibitors of sglt-2